NASDAQ:OPTN - OptiNose Stock Price, Forecast & News

$8.57

-0.25 (-2.83 %)

(As of 01/20/2020 04:00 PM ET)

Add

Compare

Today's Range

$8.42

Now: $8.57▼

$8.89

50-Day Range

$7.82

MA: $8.92▼

$9.97

52-Week Range

$4.44

Now: $8.57▼

$11.66

Volume131,849 shs

Average Volume170,407 shs

Market Capitalization$356.34 million

P/E RatioN/A

Dividend YieldN/A

Beta0.74

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:OPTN

Previous Symbol

CUSIPN/A

CIK1494650

Webhttp://www.optinose.com/

Phone267-364-3500

Debt

Debt-to-Equity Ratio1.67

Current Ratio4.81

Quick Ratio4.66

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$7.07 million

Price / Sales50.40

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.88 per share

Price / Book2.98

Profitability

EPS (Most Recent Fiscal Year)($2.68)

Net Income$-106,660,000.00

Net Margins-419.37%

Return on Equity-137.60%

Return on Assets-61.40%

Miscellaneous

Employees102

Outstanding Shares41,580,000

Market Cap$356.34 million

Next Earnings Date3/4/2020 (Estimated)

OptionableNot Optionable

Receive OPTN News and Ratings via Email

Sign-up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter.

OptiNose (NASDAQ:OPTN) Frequently Asked Questions

What is OptiNose's stock symbol?

OptiNose trades on the NASDAQ under the ticker symbol "OPTN."

How were OptiNose's earnings last quarter?

OptiNose Inc (NASDAQ:OPTN) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.69) EPS for the quarter, hitting analysts' consensus estimates of ($0.69). The company earned $12.40 million during the quarter, compared to analyst estimates of $8.56 million. OptiNose had a negative return on equity of 137.60% and a negative net margin of 419.37%. View OptiNose's Earnings History.

When is OptiNose's next earnings date?

OptiNose is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for OptiNose.

What price target have analysts set for OPTN?

5 equities research analysts have issued 1 year price targets for OptiNose's stock. Their forecasts range from $20.00 to $29.00. On average, they anticipate OptiNose's share price to reach $25.00 in the next year. This suggests a possible upside of 191.7% from the stock's current price. View Analyst Price Targets for OptiNose.

What is the consensus analysts' recommendation for OptiNose?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OptiNose.

What are Wall Street analysts saying about OptiNose stock?

Here are some recent quotes from research analysts about OptiNose stock:

1. According to Zacks Investment Research, "OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and throat or ENT and allergy specialists. The company's lead product consists of XHANCE nasal polyps, XHANCE Chronic sinusitis, OPN-300, OPN- 021 and AVP-825 which are in clinical stage. OptiNose Inc. is headquartered in Pennsylvania, USA. " (1/15/2020)
2. Cantor Fitzgerald analysts commented, ". Post 1Q19, we are reiterating our OW rating and $27 12- month PT for OPTN. Despite a lumpy Xhance initial launch, we believe we are beginning to see Xhance gain traction, which supports our confidence in the peak sales potential of the product. In 2019, we believe the increased access, better affordability, the sales force expansion and increased awareness of the good efficacy data should continue to drive script growth throughout the year, and beyond. OPTN has evolved aspects of its launch strategy, which we view as positive and believe are beginning to pay dividends. We continue to take a conservative approach to Xhance revenue in 2019 while the updated launch strategy is fully implemented." (5/9/2019)

Has OptiNose been receiving favorable news coverage?

Headlines about OPTN stock have trended extremely negative on Monday, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. OptiNose earned a daily sentiment score of -5.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for OptiNose.

Who are some of OptiNose's key competitors?

Some companies that are related to OptiNose include BELLUS Health (BLUSF), Nabriva Therapeutics (NBRV), Endo International (ENDP), TG Therapeutics (TGTX), Madrigal Pharmaceuticals (MDGL), Y-mAbs Therapeutics (YMAB), Supernus Pharmaceuticals (SUPN), Myovant Sciences (MYOV), Endonovo Therapeutics (ENDV), Athenex (ATNX), ZEALAND PHARMA/S (ZEAL), Enanta Pharmaceuticals (ENTA), NextCure (NXTC), Portola Pharmaceuticals (PTLA) and IGM Biosciences (IGMS).

What other stocks do shareholders of OptiNose own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OptiNose investors own include Idera Pharmaceuticals (IDRA), Proteostasis Therapeutics (PTI), Syndax Pharmaceuticals (SNDX), Clearside Biomedical (CLSD), Arcos Dorados (ARCO), Coherus Biosciences (CHRS), Resonant (RESN), OrganiGram (OGI), SVB Financial Group (SIVB) and Stemline Therapeutics (STML).

Who are OptiNose's key executives?

OptiNose's management team includes the folowing people:

Mr. Peter K. Miller, CEO & Director (Age 58)
Dr. Ramy A. Mahmoud M.D., M.P.H., Pres & COO (Age 54)
Mr. Keith Alan Goldan, Chief Financial Officer (Age 48)
Mr. Michael F. Marino, Chief Legal Officer & Corp. Sec. (Age 43)
Mr. Thomas E. Gibbs, Exec. VP & Chief Commercial Officer (Age 47)

When did OptiNose IPO?

(OPTN) raised $101 million in an IPO on Friday, October 13th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO.

Who are OptiNose's major shareholders?

OptiNose's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Mesirow Financial Investment Management Inc. (0.08%). Company insiders that own OptiNose stock include Avista Capital Partners Ii Gp,, Joseph C Scodari, Peter K Miller, Robert P O'neil, Sriram Venkataraman and Thomas Edward Gibbs. View Institutional Ownership Trends for OptiNose.

Which institutional investors are buying OptiNose stock?

OPTN stock was bought by a variety of institutional investors in the last quarter, including Mesirow Financial Investment Management Inc.. Company insiders that have bought OptiNose stock in the last two years include Joseph C Scodari, Peter K Miller, Robert P O'neil and Thomas Edward Gibbs. View Insider Buying and Selling for OptiNose.

How do I buy shares of OptiNose?

Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is OptiNose's stock price today?

One share of OPTN stock can currently be purchased for approximately $8.57.

How big of a company is OptiNose?

OptiNose has a market capitalization of $356.34 million and generates $7.07 million in revenue each year. The company earns $-106,660,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. OptiNose employs 102 workers across the globe.View Additional Information About OptiNose.

What is OptiNose's official website?

The official website for OptiNose is http://www.optinose.com/.

How can I contact OptiNose?

OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected]

MarketBeat Community Rating for OptiNose (NASDAQ OPTN)

Community Ranking:		2.4 out of 5 ( )
Outperform Votes:		203 (Vote Outperform)
Underperform Votes:		223 (Vote Underperform)
Total Votes:		426

MarketBeat's community ratings are surveys of what our community members think about OptiNose and other stocks. Vote "Outperform" if you believe OPTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPTN will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 1/20/2020 by MarketBeat.com Staff

Featured Article: What does the Producer Price Index (PPI) tell investors?

Your Ultimate Investing Toolkit

Just $1.00 for your first month.